CIK细胞配合二线化疗治疗晚期肺癌的疗效分析
|
摘要
目的分析细胞因子诱导杀伤(CIK)细胞配合二线化疗治疗晚期肺癌患者的临床效果。方法 104例晚期肺癌患者,随机分成实验组和对照组,每组52例。对照组患者采用二线化疗方法进行治疗,实验组患者在对照组基础上使用CIK细胞进行联合治疗。比较两组患者治疗前后T细胞群改善情况及不良反应发生情况。结果治疗前,两组患者CD3+、CD56+、CD4+、CD4+/CD8+比较差异均无统计学意义(P>0.05);治疗后,实验组患者CD3+、CD56+、CD4+、CD4+/CD8+均高于本组治疗前,且实验组高于对照组,差异具有统计学意义(P<0.05)。实验组患者白细胞减少发生率为11.5%、胃肠不适发生率为19.2%、血红蛋白降低发生率为11.5%,均低于对照组的28.8%、38.5%、28.8%,差异均具有统计学意义(P<0.05)。结论采用CIK细胞配合二线化疗治疗晚期肺癌患者,疗效显著,安全性高,值得临床大力推广。
Objective To analyze the clinical effect of cytokine induced killer(CIK) cells combined with second-line chemotherapy for the treatment of advanced lung cancer patients. Methods A total of 104 advanced lung cancer patients were randomly divided into experimental group and control group, with 52 cases in each group. The control group received second-line chemotherapy, and the experimental group received combined therapy with CIK cell on the basis of the control group. Comparison were made on improvement of T cell group before and after treatment and the occurrence of adverse reactions between two groups. Results Before treatment, both groups had no statistically significant difference in CD3+, CD56+, CD4+ and CD4+/CD8+(P>0.05). After treatment, the experimental group had higher CD3+, CD56+, CD4+ and CD4+/CD8+ than before treatment, and the experimental group was higher than the control group. Their difference was statistically significant(P<0.05). The experimental group had incidence of leukocyte reduction as 11.5%, incidence of gastrointestinal discomfort as 19.2% and incidence of hemoglobin reduction as 11.5%, which were all lower than 28.8%, 38.5% and 28.8% in the control group, and their difference was statistically significant(P<0.05). Conclusion Combination of CIK cells and second-line chemotherapy shows remarkable efficacy in the treatment of advanced lung cancer with high safety, and it is worthy of clinical promotion.
Objective To analyze the clinical effect of cytokine induced killer(CIK) cells combined with second-line chemotherapy for the treatment of advanced lung cancer patients. Methods A total of 104 advanced lung cancer patients were randomly divided into experimental group and control group, with 52 cases in each group. The control group received second-line chemotherapy, and the experimental group received combined therapy with CIK cell on the basis of the control group. Comparison were made on improvement of T cell group before and after treatment and the occurrence of adverse reactions between two groups. Results Before treatment, both groups had no statistically significant difference in CD3+, CD56+, CD4+ and CD4+/CD8+(P>0.05). After treatment, the experimental group had higher CD3+, CD56+, CD4+ and CD4+/CD8+ than before treatment, and the experimental group was higher than the control group. Their difference was statistically significant(P<0.05). The experimental group had incidence of leukocyte reduction as 11.5%, incidence of gastrointestinal discomfort as 19.2% and incidence of hemoglobin reduction as 11.5%, which were all lower than 28.8%, 38.5% and 28.8% in the control group, and their difference was statistically significant(P<0.05). Conclusion Combination of CIK cells and second-line chemotherapy shows remarkable efficacy in the treatment of advanced lung cancer with high safety, and it is worthy of clinical promotion.
引文
[1]张晓,杨琼英,林国桢.大气污染与居民肺癌发病及死亡灰色关联分析.中国公共卫生,2014,30(2):165-170.
[2]沈永洲,杜灵彬,汪祥辉.2000~2009年浙江省肿瘤登记地区肺癌流行趋势分析.中国肿瘤,2014,23(3):175-179.
[3]李娜,王燕.23例肺癌并发肺栓塞的临床分析.中国肺癌杂志,2014,17(3):254-259.
[4]董爽,于世英.肿瘤化疗所致恶心呕吐现状调查.中国循证医学杂志,2013,13(6):687-691.
[5]曹玲玲.恶性实体肿瘤并发DIC与急性白血病并发DIC的对比研究.山西医科大学,2016.
[6]杨婷,高清平.不同成因DIC临床表现及转归与患者凝血指标和临床评分的关系.微循环学杂志,2016,26(3):21-26.
[7]曾辉,宋文玲,韩蓉,等.CIK细胞联合二线化疗治疗晚期肺癌的临床效果观察.临床肺科杂志,2015,20(10):1787-1790.
[8]王金烁,谢泽新,李慧杰,等.自体CIK细胞联合化疗二线治疗晚期非小细胞肺癌疗效观察.河北医药,2015(10):1477-1479.
[9]朱红革,展翼翼,周欣,等.自体CIK联合化疗治疗晚期非小细胞肺癌的临床疗效分析.医药,2016(1):00269-00270.
[10]魏成明,晏军,王琳,等.DC-CIK细胞联合化疗治疗老年晚期非小细胞肺癌的疗效观察.实用癌症杂志,2015(4):572-574.
[2]沈永洲,杜灵彬,汪祥辉.2000~2009年浙江省肿瘤登记地区肺癌流行趋势分析.中国肿瘤,2014,23(3):175-179.
[3]李娜,王燕.23例肺癌并发肺栓塞的临床分析.中国肺癌杂志,2014,17(3):254-259.
[4]董爽,于世英.肿瘤化疗所致恶心呕吐现状调查.中国循证医学杂志,2013,13(6):687-691.
[5]曹玲玲.恶性实体肿瘤并发DIC与急性白血病并发DIC的对比研究.山西医科大学,2016.
[6]杨婷,高清平.不同成因DIC临床表现及转归与患者凝血指标和临床评分的关系.微循环学杂志,2016,26(3):21-26.
[7]曾辉,宋文玲,韩蓉,等.CIK细胞联合二线化疗治疗晚期肺癌的临床效果观察.临床肺科杂志,2015,20(10):1787-1790.
[8]王金烁,谢泽新,李慧杰,等.自体CIK细胞联合化疗二线治疗晚期非小细胞肺癌疗效观察.河北医药,2015(10):1477-1479.
[9]朱红革,展翼翼,周欣,等.自体CIK联合化疗治疗晚期非小细胞肺癌的临床疗效分析.医药,2016(1):00269-00270.
[10]魏成明,晏军,王琳,等.DC-CIK细胞联合化疗治疗老年晚期非小细胞肺癌的疗效观察.实用癌症杂志,2015(4):572-574.